We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut January 31, 2025 Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...